Vigo shares are to spin off their medical device business and list in Hong Kong.

On September 17th, Shandong Vigo announced that it was considering the possibility of splitting up its one-time medical device business in radiology, vascular, cardiology and oncology intervention surgery and listing independently on an accredited stock exchange.
if a spin-off or listing is possible, Shandong Vigo will split up the business in accordance with the guidelines for the application of the Listing Rules of the Stock Exchange securities, and will make further announcements in due course in accordance with the provisions of the Listing Rules.
The announcement comes after Reuters' IFR reported that Shandong Vigo may consider splitting its subsidiary Argon Medical Devices, possibly in Hong Kong, which is expected to be valued at $2bn-$3bn at the time of the listing.
according to the annual report, Shandong Vico includes eight major business areas: clinical care, trauma management, blood management, pharmaceutical packaging, medical examination, anesthesia and surgery, orthopaedic products and interventional products.
2019, Shandong Weigao achieved revenue of 10.36 billion yuan, up 17.7% YoY, including tumor intervention, vascular intervention, imaging intervention, a total revenue of about 1.66 billion yuan, an increase of 14.6% over last year, accounting for 16% of total revenue.
as far as management is concerned, Shandong Weigao is currently divided into six operating divisions: medical device products, orthopaedic products, intervention products, pharmaceutical packaging products, blood management products and other, of which intervention products are produced by Ai Wei.
is mainly engaged in the production and sale of medical devices for interventional radiology, angioscology, interventional cardiology and oncology, shandong Wei high overseas expansion platform and interventional product business expansion platform.
January 23, 2018, WW Holding, an 89.81% equity subsidiary of Shandong Vigo, completed the acquisition of 100% of Eython for 5.45 billion yuan.
Shandong Wei senior officials network information shows that the company's 2016 net income of 225 million U.S. dollars, when the acquisition, its fist products including puncture biopsy products, vascular intervention products and drainage catheters, mainly serving the oncology and cardiovascular departments of interventional treatment, core products in the U.S. market share are in the top three, in the major markets around the world also have a high visibility.
Ayung puncture biopsy products and ancillary supplies products mainly include BioPince, vascular intervention products mainly include Opto Elite lower cavity venous filter, mechanical thrombosis removal equipment and external center venous catheter;
Weigao Orthopaedics split listing in addition to considering splitting the one-time medical device business involved in surgery, on June 11, Vico shares announced that it is proposed to spin off Shandong Weigao Orthopaedic Materials Co., Ltd. and independently listed on The Board.
board announced at the time that Vico Orthopaedics had submitted an application to the Shanghai Stock Exchange for listing on the board.
as early as December 30, 2019, Vico shares announced that insider information suggested the spin-off of Vico Orthopaedics and listing on a Chinese stock exchange.
the same day, The financial advisor of Vico Orthopaedics submitted an application to the Shandong Regulatory Bureau of the China Securities Regulatory Commission for pre- listing counseling on the proposed spin-off.
orthopaedics is mainly engaged in the manufacture and sale of implantable orthopaedic medical devices, including spinal, trauma and joint products.
also produce surgical instruments and tools for spinal, trauma and joint implants.
announcement, Vico shares currently hold about 80.53 percent of Vico Orthopaedics, directly and indirectly.
is expected to become a subsidiary of Vico's shares when it completes the listing of the company.
according to the 2019 Annual Report, Vico ag has a wide range of products, including clinical care, trauma management, blood management, pharmaceutical packaging, medical testing, anesthesia and surgery-related products, orthopaedics and interventional products in eight key business areas.
2019, Vico's orthopaedic business achieved a turnover of approximately $1,556 million, an increase of 31.8% over 2018, with revenue accounting for 15% of total turnover and an increase of 1.6% over 2018.
reason is that Vigo shares through further consolidate the market position in the field of spine, increase the marketing of joint products, as well as channel sinking, build logistics platform and other measures, better to stimulate sales growth.
according to the Shanghai Securities News, Sun Ingrui, deputy director of the regulatory department of listed companies at the CSRC, has said that a spin-off listing has three benefits for listed companies.
First, businesses can focus on areas of expertise, second, information is more transparent, independently listed companies need to be independently disclosed after the break-up, third, the valuation is more reasonable, different businesses have independent market positioning, independent valuation, after the spin-off of the enterprise valuation is more reasonable.
.